{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:42:19Z","timestamp":1777956139953,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.amjmed.2026.02.012","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:10:39Z","timestamp":1771027839000},"page":"708-717.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implications of 2023 ACR\/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4508-1812","authenticated-orcid":false,"given":"B.C.","family":"Geertsema-Hoeve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Stam-Slob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Eikenboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.M.","family":"Frijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-6731","authenticated-orcid":false,"given":"R.J.","family":"Goekoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.L.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-2487","authenticated-orcid":false,"given":"A.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-1420","authenticated-orcid":false,"given":"A.J.G.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kooiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-8154","authenticated-orcid":false,"given":"J.J.E.","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"Lely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-1597","authenticated-orcid":false,"given":"T.E.","family":"van Mens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.G.","family":"van der Molen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-3634","authenticated-orcid":false,"given":"M.A.","family":"van de Ree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.T.","family":"Urbanus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-5227","authenticated-orcid":false,"given":"J.","family":"Westerink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Limper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9751","key":"10.1016\/j.amjmed.2026.02.012_bib0001","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.amjmed.2026.02.012_bib0002","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.012_bib0003","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.074","article-title":"The performance of 2023 American College of Rheumatology (ACR) \/European Alliance of Associations for Rheumatology (EULAR) antiphospholipid syndrome classification criteria in a real-world rheumatology department","volume":"16","author":"Usta","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"5","key":"10.1016\/j.amjmed.2026.02.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15175","article-title":"Assessment and comparison of the 2023 ACR\/EULAR APS criteria with the revised Sapporo criteria","volume":"27","author":"Vasi","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.012_bib0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.012_bib0006","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"167","key":"10.1016\/j.amjmed.2026.02.012_bib0007","first-page":"D7158","article-title":"Veneuze trombo-embolie bij antifosfolipidensyndroom","volume":"16","author":"van Mens","year":"2023","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"19","key":"10.1016\/j.amjmed.2026.02.012_bib0008","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/diagnostics14192162","article-title":"Impact of the 2023 ACR\/EULAR classification criteria in women with primary antiphospholipid syndrome during pregnancy","volume":"14","author":"Mart\u00ednez-Taboada","year":"2024","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.amjmed.2026.02.012_bib0009","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.amjmed.2026.02.012_bib0010","first-page":"CD012852","article-title":"Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss","volume":"5","author":"Hamuly\u00e1k","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.amjmed.2026.02.012_bib0011","first-page":"107","article-title":"The European Society of Human Reproduction and Embryology","volume":"20","year":"2022","journal-title":"Recurrent Pregnancy Loss"},{"key":"10.1016\/j.amjmed.2026.02.012_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109359","article-title":"Performance of new 2023 ACR\/EULAR antiphospholipid syndrome classification criteria in young patients admitted for pulmonary embolism","volume":"252","author":"Bouzid","year":"2025","journal-title":"Thromb Res"},{"issue":"SI","key":"10.1016\/j.amjmed.2026.02.012_bib0013","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.amjmed.2026.02.012_bib0014","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1007\/s10067-024-07144-7","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria identify patients at high risk of complications","volume":"43","author":"Castillo-Mart\u00ednez","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.012_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.amjmed.2026.02.012_bib0016","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.39668","article-title":"Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes","volume":"68","author":"Yelnik","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.012_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.amjmed.2026.02.012_bib0018","first-page":"605","article-title":"Classification criteria for the antiphospholipid syndrome: not the same as diagnostic criteria for antiphospholipid syndrome","volume":"50","author":"Favaloro","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.amjmed.2026.02.012_bib0019","first-page":"5","volume":"28","author":"Horowitz","year":"2010"},{"issue":"8","key":"10.1016\/j.amjmed.2026.02.012_bib0020","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jtha.2024.04.016","volume":"22","author":"Vandevelde","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.012_bib0021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jtha.2024.09.021","volume":"23","author":"Meroni","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.012_bib0022","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.jtha.2023.04.001","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"21","author":"Vandevelde","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2026.02.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109804","article-title":"Beyond the classics: The emerging value of anti-phosphatidylserine\/prothrombin antibodies in antiphospholipid syndrome","volume":"256","author":"Ding","year":"2023","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.012_bib0024","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/rth2.12472","article-title":"DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples","volume":"5","author":"Baker","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.012_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.14633","article-title":"The (non-)sense of detecting anti-cardiolipin and anti-\u03b22glycoprotein I IgM antibodies in the antiphospholipid syndrome","volume":"18","author":"Chayoua","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.012_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100011","article-title":"Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti\u2013\u03b22-glycoprotein I antibody titers","volume":"7","author":"Noordermeer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.amjmed.2026.02.012_bib0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2022.01.021","article-title":"Warfarin monitoring and interference by lupus anticoagulant in patients with antiphospholipid syndrome","volume":"211","author":"Jepsen","year":"2022","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.amjmed.2026.02.012_bib0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1018722829498","article-title":"Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination","volume":"9","author":"Bijsterveld","year":"2000","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.amjmed.2026.02.012_bib0029","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.amjmed.2026.02.012_bib0030","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.amjmed.2026.02.012_bib0031","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.amjmed.2026.02.012_bib0032","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus Vitamin K antagonist in antiphospholipid syndrome","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.amjmed.2026.02.012_bib0033","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjh.19635","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"205","author":"Arachchillage","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.amjmed.2026.02.012_bib0034","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"8","key":"10.1016\/j.amjmed.2026.02.012_bib0035","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.3390\/ijms22084200","article-title":"Platelets and the antiphospholipid syndrome","volume":"22","author":"Huang","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.amjmed.2026.02.012_bib0036","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2026.02.012_bib0037","doi-asserted-by":"crossref","first-page":"108164","DOI":"10.1016\/j.cct.2025.108164","article-title":"Comparison of clopidogrel-based antiplatelet therapy versus warfarin as a secondary prevention strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE): rationale and design of a prospective, randomized, open-label, blinded-endpoint trial","volume":"160","author":"Yang","year":"2026","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.amjmed.2026.02.012_bib0038","first-page":"98","article-title":"Diagnosing and treating antiphospholipid syndrome: a consensus paper","volume":"77","author":"Limper","year":"2019","journal-title":"Neth J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2026.02.012_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.amjmed.2026.02.012_bib0040","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"34","key":"10.1016\/j.amjmed.2026.02.012_bib0041","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"2\u20133","key":"10.1016\/j.amjmed.2026.02.012_bib0042","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12026-013-8407-x","article-title":"Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative","volume":"56","author":"Coloma Baz\u00e1n","year":"2013","journal-title":"Immunol Res"},{"issue":"5","key":"10.1016\/j.amjmed.2026.02.012_bib0043","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/17474086.2021.1923474","article-title":"Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines","volume":"14","author":"Pires Da Rosa","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.amjmed.2026.02.012_bib0044","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.012_bib0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International clinical database and repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:15:20Z","timestamp":1777943720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0002934326001166"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.02.012","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of 2023 ACR\/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}